On a DART-reported annual basis, revenue fell from KRW 456.7 billion in 2022 to KRW 369.5 billion in 2023, down 19.1%, and then to KRW 267.5 billion in 2024, down 27.6%, before jumping to KRW 651.4 billion in 2025, up 143.5%. Among 2022-2025, 2025 was the largest year and 2024 was the smallest.
Operating profit of KRW 115 billion in 2022 turned into an operating loss of KRW 12 billion in 2023, widened to an operating loss of KRW 138.4 billion in 2024, and then narrowed to an operating loss of KRW 123.5 billion in 2025. The company recorded losses for three consecutive years from 2023 to 2025.
The operating margin moved from 25.2% in 2022 to -3.2% in 2023, -51.7% in 2024 and -19.0% in 2025, and the deepest margin loss came in the year with the smallest revenue.
Net income attributable to controlling shareholders fell from KRW 122.5 billion in 2022 to KRW 22.3 billion in 2023, down 81.8%, turned into a loss of KRW 53.9 billion in 2024, and widened to a loss of KRW 57.4 billion in 2025.
Net income including non-controlling interests was a loss of KRW 50.1 billion in 2024 and a loss of KRW 56.2 billion in 2025, a separate figure from controlling-shareholder results.
Quarterly operating losses moved from KRW 19.4 billion in the third quarter of 2025 to KRW 51.6 billion in the fourth quarter, then narrowed to KRW 44.5 billion, KRW 15.7 billion and KRW 11.2 billion across the first three quarters of 2026.
Revenue peaked at KRW 184.2 billion in the fourth quarter of 2025, fell to KRW 168.6 billion and KRW 155.7 billion in the first two quarters of 2026, and recovered to KRW 182.4 billion in the third quarter of 2026, up 21.0% from a year earlier.
Controlling-shareholder net income of KRW 10.5 billion in the third quarter of 2026 turned positive from a KRW 17.9 billion loss in the prior quarter, though it was down 57.0% from KRW 24.5 billion a year earlier. Controlling-shareholder net losses over the last four quarters total KRW 98.6 billion.
Reported drivers of the first-quarter 2026 loss increase were higher R&D spending, Songdo-related costs, higher depreciation and the end of a prior-year inventory valuation reversal on flu vaccines.